ADO (2-Aminoethanethiol Dioxygenase) Drug Discovery Landscape & Assay Solutions
- By admin
- 03 Jul 2026
- Comments
Metabolic Pathway Analysis, Ferroptosis Modulation, and High-Purity Enzymatic Reagents for Cysteamine Metabolism Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADO drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADO Recombinant Protein (Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native folding. |
View ADO Products |
| Gene Delivery | ADO Lentivirus Particles Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. |
View ADO Products |
| Benchmark Ab | Anti-ADO Polyclonal Antibody Recombinant positive control for Western/ELISA. |
View ADO Products |
| Validator | ADO siRNA Set (3 unique targets) For knockdown verification and specificity controls. |
View ADO Products |
| Pathway Partner 1 | CDO (Cysteine Dioxygenase) Synergistic sulfur metabolism enzyme; co-targeting potential. |
View CDO Products |
| Pathway Partner 2 | SLC6A6 (Taurine Transporter) Downstream hypotaurine/taurine transport; metabolic flux analysis. |
View SLC6A6 Products |
| Ferroptosis Node | GPX4 (Glutathione Peroxidase 4) Functional connection to ferroptosis regulation. |
View GPX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Metal Cofactor Dependency (Fe(II) binding) | Sequence Verified active site (His-X-His motif); Theoretical MW confirmation; Metal-binding competent folding |
| Enzyme Kinetics & Substrate Specificity | High-purity (>95%) protein for accurate Km/Kcat determination; Low endotoxin (<1EU/ug) to prevent cellular assay interference |
| Subcellular Localization Studies | Overexpression Lentivirus with C-terminal V5 tag for microscopy validation; Native regulation preserved |
| Pathway Integration Analysis | Matched CDO and SLC6A6 protein panel available for comparative enzymatic studies |
Live ADO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADO-targeted therapeutics is emerging from preclinical metabolic research, with major academic players investigating its role in ferroptosis modulation and cystinosis treatment. As understanding of sulfur metabolism deepens, ADO represents a novel intervention point for diseases characterized by oxidative stress and cysteamine accumulation. The next wave of R&D is targeting enzyme stabilization for cystinosis and inhibition for cancer ferroptosis sensitization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement | Academic Consortiums | Cystinosis (Rare Metabolic) | Activity Assay (Need metal-cofactor competent protein) |
| Small Molecule Inhibitors | Early Stage Biotech | Solid Tumors (Ferroptosis) | High-throughput Screening (Need purified WT and mutant enzymes) |
| Metabolic Modulators | Research Institutes | Neurodegeneration | Pathway Flux Analysis (Need matched CDO/ADO protein pairs) |